stroke
Genedrive Point-of-Care PGx Test for Stroke Patients Nabs UKCA Mark
The test can determine which stroke patients may respond to clopidogrel treatment in about one hour.
Genedrive, U of Manchester Collaborate to Further Validate CYP2C19 Test
Genedrive's CYP2C19 ID Kit will be evaluated by multiple stakeholders in a program funded by Innovate UK and the UK Innovation Accelerator.
UK's NICE Recommends Genetic Testing for Therapy Selection in Stroke Patients
Clopidogrel is less effective at preventing subsequent strokes in patients with certain variations in the CYP2C19 gene and testing could aid treatment selection.
As part of the program, point-of-care tests sold by Genedrive and Genomadix will be assessed, as well as laboratory-developed tests used within the UK National Health Service.
The companies were recently awarded a €2.4 million Eurostars grant to support the development and validation of the assay.
Aug 17, 2021
Jun 4, 2019
May 1, 2019
Oct 3, 2018
Nov 11, 2016